(Total Views: 488)
Posted On: 09/16/2021 3:25:06 PM
Post# of 153903
Thanks, Enjay, Ohm,
So, we are definitely missing genetic sequences that are necessary to prove efficacy in order to get a BTD in cancer. And it's only on 10 patients. And Amarex has that information. And it's not clear whether CYDY will sue Amarex or vice versa..
This data seems tremendously inexpensive relative to the cost of delay - a BTD would surely increase the price at which CYDY can issue new shares. My only workable guess is that the data is being held hostage to extort a really big number related to the unwind of the rest of a multi-year contract between the firms.
Still seems stupidly ugly. Other interpretations?
So, we are definitely missing genetic sequences that are necessary to prove efficacy in order to get a BTD in cancer. And it's only on 10 patients. And Amarex has that information. And it's not clear whether CYDY will sue Amarex or vice versa..
This data seems tremendously inexpensive relative to the cost of delay - a BTD would surely increase the price at which CYDY can issue new shares. My only workable guess is that the data is being held hostage to extort a really big number related to the unwind of the rest of a multi-year contract between the firms.
Still seems stupidly ugly. Other interpretations?
(2)
(0)
